HTS and Proteomics

HTS 和蛋白质组学

• 批准号: 8011760
• 负责人: Julian P Whitelegge
• 金额: $ 39.7万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-08-05 至 2015-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8011760
• 关键词: Arts; Biological; Cells; Chemical Structure; Chemicals; Data; Databases; Family; Funding; Housing; Lead; Mass Spectrum Analysis; Measures; Mining; Molecular Profiling; Pathway interactions; Pharmaceutical Preparations; Pharmacologic Substance; Pilot Projects; Play; Proteomics; Radiation; Research; Research Project Grants; Role; Services; Structure-Activity Relationship; Technology; Work; analog; chemical synthesis; cheminformatics; data mining; design; driving force; drug discovery; high throughput screening; improved; novel; pharmacophore; response; small molecule libraries

Core D is critical for the central tenet ofthe UCLA-CMCR, which is that classes of mitigators of radiation damage can be identified by their chemical structures and/or the biological pathways that they utilize. Core D has provided and will continue to provide the technological driving force behind the work ofthe projects in high-throughput screening (HTS) of small molecule libraries with the aim of discovering novel mitigators of radiation damage. Core D centralizes HTS in a state-of-the-art facility that has already proven its value to the UCLA-CMCR, with several families of lead compounds identified. Additionally, in order to deal with the data that has been generated and to provide it to the CMCR in a form in which it can be mined for structureactivity relationships and other relevant chemical and biological information Core D, through pilot research funding, has established a relationship with Collaborative Drug Discovery (CDD) to use its an industrialstrength database for these purposes. Access to this data is available to other CMCRs. Now that families of lead compounds have been identified, with more to come. Core D has been further expanded to include pharmaceutical chemists under Dr. Jung, who will play a central role in design and synthesis of analogues of active compounds to identify chemical structures responsible for activity, to improve their drug-like qualities, and their efficacy. This relationship also was initiated through pilot research funding. Finally, Core D provides proteomics primarily in the form of mass spectrometry to seek molecular signatures ofthe biological pathways utilized by effective mitigators so as to probe mechanism of action of these compounds.

核心 D 对于 UCLA-CMCR 的中心原则至关重要，即辐射缓解剂类别 损伤可以通过它们的化学结构和/或它们利用的生物途径来识别。核心D 已经并将继续提供项目工作背后的技术驱动力 小分子文库的高通量筛选（HTS），旨在发现新的缓解剂 辐射损伤。 Core D 将 HTS 集中在最先进的设施中，该设施已经向业界证明了其价值 UCLA-CMCR，确定了几个先导化合物家族。另外，为了处理数据 已生成并以可开采结构活性的形式提供给 CMCR 关系和其他相关化学和生物信息 核心 D，通过试点研究 资金，已与协作药物发现（CDD）建立了关系，以利用其工业优势 用于这些目的的数据库。其他 CMCR 可以访问此数据。现在那些家庭 先导化合物已经被发现，而且还会有更多的化合物被发现。核心 D 已进一步扩展，包括 Jung 博士领导下的药物化学家将在类似物的设计和合成中发挥核心作用 活性化合物，以确定负责活性的化学结构，以提高其药物质量， 及其功效。这种关系也是通过试点研究资助启动的。最后是核心D 主要以质谱分析的形式提供蛋白质组学，以寻找生物的分子特征 有效缓解剂利用的途径，以探究这些化合物的作用机制。